Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=147 Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Number of Participants With Pathologic Response by HR-deficiency (HRD) Status — 9; 2; 10; 4 Participants
Phase 3 N=182 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Phase 2 N=16 Vaccination of Triple Negative Breast Cancer Patients
Triple Negative Breast Cancer · Breast Neoplasms
Primary: Safety and Tolerability Adverse Events — 8; 81 Total events
Phase 2 N=43 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Phase 2 N=86 Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 3 N=651 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 2 N=10 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Breast Cancer
Primary: Clinical Benefit Rate — 0; 0; 3; 7 Participants
Phase 2 N=327 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761
Phase 2 N=6 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Phase 2 N=30 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Phase 2 N=10 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Phase 2 N=40 Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: The Progression Free Survival (PFS) — 1.8 months
Phase 2 N=44 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Breast Cancer · Metastasis
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 2; 0 participants
Phase 2 N=135 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Phase 3 N=333 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population — 69; 95 Number of…
Phase 2 N=71 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Phase 3 N=191 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Breast Tumor · Breast Cancer · Cancer of the Breast
Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183
Phase 2 N=101 Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 3 N=622 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Metastatic Triple Negative Breast Cancer
Primary: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) ≥10 — 12.7; 11.6 Months — p=0.0574
Phase 2 N=15 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Phase 2 N=10 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Phase 2 N=50 A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Phase 2 N=173 Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109